6-dimethylcarbamoyl-nicotinic acid | 288083-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-dimethylcarbamoyl-nicotinic acid
• 英文别名: 6-[(dimethylamino)carbonyl]-3-pyridine carboxylic acid；6-(Dimethylcarbamoyl)nicotinic acid；6-(dimethylcarbamoyl)pyridine-3-carboxylic acid
• CAS: 288083-60-3
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: SDZYBFWUMWGSNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  70.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-dimethylcarbamoyl-nicotinic acid 在 草酰氯 作用下， 生成
  参考文献：
  名称：

  Identification of Critical Process Impurities and Their Impact on Process Research and Development

  摘要：

  The identification of low-level critical process impurities and degradants encountered during pharmaceutical development is crucial to the process development, but can often be challenging and can negatively impact the timeline of the developmental program. This is demonstrated during the early stage of process research and development of a Factor Xa inhibitor, the caprolactam 1. Details focusing on rapid identification of impurities in the active pharmaceutical ingredient (API), recognition of their root causes of formation, and the impact on process development are described.

  DOI：

  10.1021/op800067v
• 作为产物：
  描述：

  2,5-吡啶-二羧酸二甲酯 在 magnesium chloride 、 lithium hydroxide 作用下， 生成 6-dimethylcarbamoyl-nicotinic acid
  参考文献：
  名称：

  Identification of Critical Process Impurities and Their Impact on Process Research and Development

  摘要：

  The identification of low-level critical process impurities and degradants encountered during pharmaceutical development is crucial to the process development, but can often be challenging and can negatively impact the timeline of the developmental program. This is demonstrated during the early stage of process research and development of a Factor Xa inhibitor, the caprolactam 1. Details focusing on rapid identification of impurities in the active pharmaceutical ingredient (API), recognition of their root causes of formation, and the impact on process development are described.

  DOI：

  10.1021/op800067v

文献信息

• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：METHYLGENE INC

  公开号：WO2005092899A1

  公开（公告）日：2005-10-06

  The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

  这项发明涉及一系列对抑制组蛋白去乙酰化酶（HDAC）酶活性有用的化合物。该发明还提供了一种利用这些化合物抑制细胞中组蛋白去乙酰化酶的方法，以及一种利用这些HDAC抑制剂治疗细胞增殖性疾病和病况的方法。此外，该发明提供了包含这些HDAC抑制化合物和药用可接受载体的药物组合物。
• 酰胺类衍生物、其制法与医药上的用途
  申请人：上海海雁医药科技有限公司

  公开号：CN110105275B

  公开（公告）日：2020-12-29

  本发明涉及酰胺类衍生物、其制法与医药上的用途。具体地，本发明公开了式(I)化合物或其药学上可接受的盐、或立体异构体，及其制备方法和应用，式中各基团的定义详见说明书。
• Inhibitors of histone deacetylase
  申请人：Delorme Daniel

  公开号：US20050245518A1

  公开（公告）日：2005-11-03

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20070213330A1

  公开（公告）日：2007-09-13

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Lactam inhibitors of FXa and method
  申请人：Bristol-Myers Squibb Company

  公开号：US06297233B1

  公开（公告）日：2001-10-02

  Caprolactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrugs thereof, wherein n is 1 to 5; and and Y R1, R2, R3, R5, R5a, R6, R7, R8, R9 and R10 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

  提供了具有以下结构的己内酰胺抑制剂，包括其药用可接受的盐和所有立体异构体，以及其前药，其中n为1到5；并且Y，R1，R2，R3，R5，R5a，R6，R7，R8，R9和R10如本文所定义。这些化合物是因子Xa的抑制剂，因此可用作抗凝剂。还提供了一种治疗与血栓有关的心血管疾病的方法。